Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction

Multi-center study with echocardiography

Hiroshi Itoh, Katsuhisa Ishii, Katsuomi Iwakura, Fumiaki Nakamura, Toshihiko Nagano, Shin Takiuchi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We investigated the impact of lowering blood pressure (BP) with azelnidipine, a newly developed calcium channel blocker, generation on the left ventricular (LV) diastolic function and LV filling pressure by assessing non-invasive indices derived from echo Doppler study. This study evaluated 232 hypertensive patients with diastolic dysfunction. This study had two groups: (1) in which azelnidipine was administered to patients as a first-line therapy, and (2) in which amlodipine was converted to azelnidipine. Early diastolic mitral annulus velocity (e′, cm s-1), the ratio of peak E velocity to e′ velocity (E/e′ ratio) and level of brain natriuretic peptide (BNP) were measured before and, an average of, 8 months after azelnidipine treatment. In the first-line azelnidipine group, the systolic and diastolic BP reduced by 26 and 11 mm Hg, respectively. The e′ increased, and E/e′ ratio and BNP level decreased significantly. In the converted-from-amlodipine group, the systolic and diastolic BP decreased by 14 and 6 mm Hg, respectively. The e′ velocity increased, but the E/e′ ratio and BNP level did not change. In both groups, azelnidipine lowered BP and improved LV diastolic function (an increase in the e′ velocity). Possible reduction in LV filling pressure (a decrease in the E/e′ ratio and BNP level) is observed only in the first-line azelnidipine group.

Original languageEnglish
Pages (from-to)895-900
Number of pages6
JournalHypertension Research
Volume32
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint

Echocardiography
Hypertension
Brain Natriuretic Peptide
Blood Pressure
Amlodipine
Ventricular Pressure
Left Ventricular Function
Therapeutics
Calcium Channel Blockers
azelnidipine

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction : Multi-center study with echocardiography. / Itoh, Hiroshi; Ishii, Katsuhisa; Iwakura, Katsuomi; Nakamura, Fumiaki; Nagano, Toshihiko; Takiuchi, Shin.

In: Hypertension Research, Vol. 32, No. 10, 2009, p. 895-900.

Research output: Contribution to journalArticle

Itoh, Hiroshi ; Ishii, Katsuhisa ; Iwakura, Katsuomi ; Nakamura, Fumiaki ; Nagano, Toshihiko ; Takiuchi, Shin. / Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction : Multi-center study with echocardiography. In: Hypertension Research. 2009 ; Vol. 32, No. 10. pp. 895-900.
@article{3959cb5c2a964bcb8ededce4cd1b84c7,
title = "Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: Multi-center study with echocardiography",
abstract = "We investigated the impact of lowering blood pressure (BP) with azelnidipine, a newly developed calcium channel blocker, generation on the left ventricular (LV) diastolic function and LV filling pressure by assessing non-invasive indices derived from echo Doppler study. This study evaluated 232 hypertensive patients with diastolic dysfunction. This study had two groups: (1) in which azelnidipine was administered to patients as a first-line therapy, and (2) in which amlodipine was converted to azelnidipine. Early diastolic mitral annulus velocity (e′, cm s-1), the ratio of peak E velocity to e′ velocity (E/e′ ratio) and level of brain natriuretic peptide (BNP) were measured before and, an average of, 8 months after azelnidipine treatment. In the first-line azelnidipine group, the systolic and diastolic BP reduced by 26 and 11 mm Hg, respectively. The e′ increased, and E/e′ ratio and BNP level decreased significantly. In the converted-from-amlodipine group, the systolic and diastolic BP decreased by 14 and 6 mm Hg, respectively. The e′ velocity increased, but the E/e′ ratio and BNP level did not change. In both groups, azelnidipine lowered BP and improved LV diastolic function (an increase in the e′ velocity). Possible reduction in LV filling pressure (a decrease in the E/e′ ratio and BNP level) is observed only in the first-line azelnidipine group.",
author = "Hiroshi Itoh and Katsuhisa Ishii and Katsuomi Iwakura and Fumiaki Nakamura and Toshihiko Nagano and Shin Takiuchi",
year = "2009",
doi = "10.1038/hr.2009.119",
language = "English",
volume = "32",
pages = "895--900",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction

T2 - Multi-center study with echocardiography

AU - Itoh, Hiroshi

AU - Ishii, Katsuhisa

AU - Iwakura, Katsuomi

AU - Nakamura, Fumiaki

AU - Nagano, Toshihiko

AU - Takiuchi, Shin

PY - 2009

Y1 - 2009

N2 - We investigated the impact of lowering blood pressure (BP) with azelnidipine, a newly developed calcium channel blocker, generation on the left ventricular (LV) diastolic function and LV filling pressure by assessing non-invasive indices derived from echo Doppler study. This study evaluated 232 hypertensive patients with diastolic dysfunction. This study had two groups: (1) in which azelnidipine was administered to patients as a first-line therapy, and (2) in which amlodipine was converted to azelnidipine. Early diastolic mitral annulus velocity (e′, cm s-1), the ratio of peak E velocity to e′ velocity (E/e′ ratio) and level of brain natriuretic peptide (BNP) were measured before and, an average of, 8 months after azelnidipine treatment. In the first-line azelnidipine group, the systolic and diastolic BP reduced by 26 and 11 mm Hg, respectively. The e′ increased, and E/e′ ratio and BNP level decreased significantly. In the converted-from-amlodipine group, the systolic and diastolic BP decreased by 14 and 6 mm Hg, respectively. The e′ velocity increased, but the E/e′ ratio and BNP level did not change. In both groups, azelnidipine lowered BP and improved LV diastolic function (an increase in the e′ velocity). Possible reduction in LV filling pressure (a decrease in the E/e′ ratio and BNP level) is observed only in the first-line azelnidipine group.

AB - We investigated the impact of lowering blood pressure (BP) with azelnidipine, a newly developed calcium channel blocker, generation on the left ventricular (LV) diastolic function and LV filling pressure by assessing non-invasive indices derived from echo Doppler study. This study evaluated 232 hypertensive patients with diastolic dysfunction. This study had two groups: (1) in which azelnidipine was administered to patients as a first-line therapy, and (2) in which amlodipine was converted to azelnidipine. Early diastolic mitral annulus velocity (e′, cm s-1), the ratio of peak E velocity to e′ velocity (E/e′ ratio) and level of brain natriuretic peptide (BNP) were measured before and, an average of, 8 months after azelnidipine treatment. In the first-line azelnidipine group, the systolic and diastolic BP reduced by 26 and 11 mm Hg, respectively. The e′ increased, and E/e′ ratio and BNP level decreased significantly. In the converted-from-amlodipine group, the systolic and diastolic BP decreased by 14 and 6 mm Hg, respectively. The e′ velocity increased, but the E/e′ ratio and BNP level did not change. In both groups, azelnidipine lowered BP and improved LV diastolic function (an increase in the e′ velocity). Possible reduction in LV filling pressure (a decrease in the E/e′ ratio and BNP level) is observed only in the first-line azelnidipine group.

UR - http://www.scopus.com/inward/record.url?scp=70349996479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349996479&partnerID=8YFLogxK

U2 - 10.1038/hr.2009.119

DO - 10.1038/hr.2009.119

M3 - Article

VL - 32

SP - 895

EP - 900

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 10

ER -